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Earlier studies, mostly designed to establish the value of various pharmacologic interventions 
after myocardial infarction, have shown the prognostic value of global left ventricular function, 
measured as left ventricular ejection fraction (LVEF), in terms of mortality and re-admission 
rates for heart failure.(1-3) In chapter 2 we showed that LVEF assessed shortly after primary 
percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI), is a 
powerful predictor of long term survival. However, the post-procedural ECG is available even 
sooner. In chapter 3 it was shown that an increasing number of Q-waves on the first 12-lead 
ECG after PPCI is strongly associated with the extent of myocardial damage, measured as 
area under the curve of creatin kinase and its myocardial isoenzyme, and adverse long-term 
prognosis. This easy and low-cost method of clinical assessment after PPCI could lead to 
more focused use of advanced and expensive additional diagnostics or therapeutics. 
In chapter 4 the relationship between ST-segment resolution, residual ST-segment elevation 
and Q waves in relation to left ventricular function, size and extent of infarction, and 
microvascular injury in acute myocardial infarction measured by MRI was explored.
In chapter 5 we compared electromechanical endocardial mapping (EEM) with MRI 
and we found that EEM-derived global left ventricular functional parameters showed a 
significant underestimation compared to MRI. However, regional parameters appeared to 
be useful indicators of dysfunctional myocardial segments. Although there were substantial 
differences in global left ventricular functional parameters between EEM and MRI, a good 
correlation was found between the surface-area of the EEM-map with a unipolar voltage 
below 6,9 mV and MRI infarct-size.(4) Segmental analyses showed that EEM can be used to 
determine both regional function and extent of infarction in patients with a large myocardial 
infarction. Although regional data showed good correlation with MRI, convincing cut-off 
values for EEM-parameters could not be established. Exact pinpointing of myocardial areas 
benefiting from direct injection of therapeutics remains difficult.
Since residual left ventricular function was shown to be one of the most powerful predictors 
of prognosis after primary PCI for STEMI, every effort should be made to conserve, and 
possibly even improve, left ventricular function after STEMI. Cell therapy has been a 
promising new modality in the field of post-STEMI care, which has rendered mixed results 







multicenter trial, a pilot-study was conducted to establish the safety and feasibility of all 
study related procedures (chapter 7). This study indicated that intracoronary infusion of 
autologous bone marrow derived mononuclear cells after recent myocardial infarction is 
safe in a multicenter setting. At 4 months follow-up a modest but significant increase in 
global and regional LV function was observed, with a concomitant decrease in infarct-size. 
After successfully completing the pilot-study, the multicenter HEBE trial could be initiated 
(chapter 8 and 9). The rationale behind the three arm-armed study design is to test the 
hypothesis that the beneficial effects of cell-therapy on left ventricular function cannot be 
completely attributed to the formation of new cardiac myocytes or endothelial cells, but 
that these positive effects could also be a combined effect of all mononuclear cells, through 
the release of growth factors and cytokines. Intracoronary infusion was chosen as mode 
of delivery, since the benefits of avoiding local injection were considered to outweigh the 
obvious drawback of decreased local cell-retention.(11) The rationale behind the choice for 
MRI as imaging modality for the primary end-point of the study is its ability to combine left 
ventricular function analysis with infarct-size analyses. 
The HEBE trial showed no benefit of infusion of autologous bone marrow derived progenitor 
cells after STEMI. Research in this field will most likely continue, since cell therapy remains 
a very appealing concept. In the future trials with other cell types or pre-treatment of cells 
may be conducted. However, since the procedures involved in cell therapy are relatively 
invasive and time-consuming, great care should be taken to identify those patients in which 
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